Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | President of R&D | March 04, 2020 | March 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tectonic Therapeutic, Inc.
Report date March 04, 2020 · Filed March 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.44 · Expires 2030-03-03 | Direct | 76,000 |
Reported balance
After 2020-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-04 · Grant · Acquired 76,000 · Balance 76,000 F1: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 17,536 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2029-06-10 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 1,333 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.15 · Expires 2030-05-18 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 635 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.60 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.30 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-18 · Disposition to issuer · Disposed 2,124 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2033-05-26 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 8 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 7 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $2.55 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 6 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,124 | Not disclosed Strike: $15.30 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 5 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,124 shares Expires 2031-06-01 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $33.60 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 4 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2031-01-08 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 635 | Not disclosed Strike: $51.15 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 3 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 635 shares Expires 2030-05-18 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 1,333 | Not disclosed Strike: $39.45 | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · derivative · entry 2 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2029-06-10 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 16:49 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 17,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001762371-26-000001 · form4-05182026_080510.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 19:27 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016362 · form4-06092025_110622.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,536 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 5, 2025 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:52 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016312 · form4-06112024_120645.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,545 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| May 26, 2023 Filed Jun 5, 2023 20:13 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001209191-23-034680 · doc4.xml · derivative · entry 2 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document |
| May 25, 2023 Filed Jun 5, 2023 20:13 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 2,666 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-23-034680 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document |
| June 01, 2022 Filed Oct 14, 2022 18:31 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 2,666 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-22-053699 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F1 · derivative.exercise_price: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F2 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. F1 · derivative.underlying_shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · balance_after: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 20:29 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 35,915 | $0.36 | $12,749.83 |
DisclosureSEC source: 0000899243-22-004248 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,678 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on January 31, 2022. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:48 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 17,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042384 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,763 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on October 29, 2021. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 16:05 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 14,010 | $0.91 | $12,749.10 |
DisclosureSEC source: 0000899243-21-031260 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,622 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on July 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 16:30 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 31,862 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000899243-21-022040 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,862 Underlying: Common Stock · 31,862 shares Expires 2021-06-01 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 18:32 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 10,537 | $1.21 | $12,749.77 |
DisclosureSEC source: 0000899243-21-018228 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,612 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs are fully vested on April 30, 2021. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:53 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 5,867 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004271 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,075 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vested on January 29, 2021. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:13 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-21-001667 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,738 Underlying: Common Stock · 40,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 18:52 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,609 | $1.74 | $11,499.66 |
DisclosureSEC source: 0000899243-20-030303 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,208 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on October 30, 2020. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 17:39 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,686 | $1.72 | $11,499.92 |
DisclosureSEC source: 0000899243-20-021014 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,686 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on July 31, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 17:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 9,530 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0000899243-20-013719 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,530 Underlying: Common Stock · 9,530 shares Expires 2030-05-18 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| April 30, 2020 Filed May 4, 2020 21:43 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,086 | $3.05 | $9,412.30 |
DisclosureSEC source: 0000899243-20-011968 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,086 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on April 30, 2020. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 16:38 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $21.44 | $0.00 |
DisclosureSEC source: 0001127602-20-009841 · form4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 3, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 16:09 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 5,827 | $3.35 | $19,520.45 |
DisclosureSEC source: 0000899243-20-001965 · doc4.xml · nonDerivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,827 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs fully vest on January 22, 2020. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 18:43 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-016682 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on July 10, 2019 and each one-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 17:09 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 293,000 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0000899243-18-031419 · doc4.xml · derivative · entry 1 Volck Birgitte · CIK 0001762371 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,000 Underlying: Common Stock · 293,000 shares Expires 2028-12-16 F1 · derivative.exercise_date: 25% of the shares vest on December 17, 2019, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.